mRNA Therapeutics for Cancer Treatment

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".

Deadline for manuscript submissions: closed (31 December 2024) | Viewed by 739

Special Issue Editors


E-Mail Website
Guest Editor
Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4067, Australia
Interests: cancer therapy; drug delivery; layered double hydroxide nanoparticles; targeted delivery; nanomedicine

E-Mail Website
Guest Editor
Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4072, Australia
Interests: nanotechnology; nanoparticle; drug delivery

Special Issue Information

Dear Colleagues,

The Nobel Prizes for 2023 have just recognized the pivotal role of mRNA in revolutionizing vaccine development against COVID-19, underscoring the immense promise of mRNA technology, not only in infectious disease management but also in the realm of cancer treatment. In light of these recent groundbreaking achievements, we are thrilled to announce a Special Issue dedicated to exploring the potential of mRNA-based treatments for cancer. This Special Issue invites your contributions to further advance our understanding of this transformative approach for cancer therapy.

Our Special Issue seeks original research articles and reviews that delve into various aspects of mRNA therapeutics for cancer, including but not limited to:

  • mRNA-based cancer vaccines: explore the development and mechanisms of personalized mRNA vaccines tailored to individual tumor profiles, and their potential to induce targeted immune responses against cancer cells;
  • Clinical insights: share the latest findings from clinical trials and studies evaluating the efficacy and safety of mRNA-based cancer therapies, shedding light on their real-world applications;
  • Synergy with existing treatments: investigate the potential synergy between mRNA therapies and other established cancer treatment modalities, such as immunotherapy and targeted therapies, to maximize patient outcomes;
  • Innovations in delivery: highlight advancements in mRNA delivery technologies, including lipid nanoparticles and other innovative approaches, that enhance the precision and effectiveness of cancer therapeutics;
  • Future directions: discuss the future directions and challenges in the field of mRNA therapeutics for cancer treatment, identifying promising avenues for further research.

Dr. Fatemeh Movahedi
Prof. Dr. Chengzhong Yu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mRNA delivery
  • cancer vaccine
  • cancer immunotherapy
  • personalized vaccine
  • messenger RNA

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

73 pages, 8826 KiB  
Review
Targeting Regulatory Noncoding RNAs in Human Cancer: The State of the Art in Clinical Trials
by Roberto Piergentili and Stefano Sechi
Pharmaceutics 2025, 17(4), 471; https://doi.org/10.3390/pharmaceutics17040471 - 4 Apr 2025
Viewed by 300
Abstract
Noncoding RNAs (ncRNAs) are a heterogeneous group of RNA molecules whose classification is mainly based on arbitrary criteria such as the molecule length, secondary structures, and cellular functions. A large fraction of these ncRNAs play a regulatory role regarding messenger RNAs (mRNAs) or [...] Read more.
Noncoding RNAs (ncRNAs) are a heterogeneous group of RNA molecules whose classification is mainly based on arbitrary criteria such as the molecule length, secondary structures, and cellular functions. A large fraction of these ncRNAs play a regulatory role regarding messenger RNAs (mRNAs) or other ncRNAs, creating an intracellular network of cross-interactions that allow the fine and complex regulation of gene expression. Altering the balance between these interactions may be sufficient to cause a transition from health to disease and vice versa. This leads to the possibility of intervening in these mechanisms to re-establish health in patients. The regulatory role of ncRNAs is associated with all cancer hallmarks, such as proliferation, apoptosis, invasion, metastasis, and genomic instability. Based on the function performed in carcinogenesis, ncRNAs may behave either as oncogenes or tumor suppressors. However, this distinction is not rigid; some ncRNAs can fall into both classes depending on the tissue considered or the target molecule. Furthermore, some of them are also involved in regulating the response to traditional cancer-therapeutic approaches. In general, the regulation of molecular mechanisms by ncRNAs is very complex and still largely unclear, but it has enormous potential both for the development of new therapies, especially in cases where traditional methods fail, and for their use as novel and more efficient biomarkers. Overall, this review will provide a brief overview of ncRNAs in human cancer biology, with a specific focus on describing the most recent ongoing clinical trials (CT) in which ncRNAs have been tested for their potential as therapeutic agents or evaluated as biomarkers. Full article
(This article belongs to the Special Issue mRNA Therapeutics for Cancer Treatment)
Show Figures

Figure 1

Back to TopTop